RandyW Posted March 8, 2010 Share Posted March 8, 2010 AstraZeneca lung cancer drug fails trial AstraZeneca has suffered a setback after it admitted today that its lung cancer treatment Recentin had failed a clinical trial designed to compare it with rival drug Avastin. In a statement, Alan Barge of Astra’s oncology division said of the Phase II/III trial: "While we recognised that challenging Avastin would be a high hurdle, it is still disappointing, despite evidence of clinical activity with Recentin, not to have met the primary endpoint in this study." AstraZeneca said it would persevere with other trials, includine one to assess Recentin combined with chemotherapy against chemotherapy alone; and another into the drug’s utility as a treatment for tumours. The group said the setback would not affect its financial guidance for 2010. Comments?manchesternews@crain.com Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.